Your browser is no longer supported. Please, upgrade your browser.
TherapeuticsMD, Inc.
Index- P/E- EPS (ttm)-0.48 Insider Own0.80% Shs Outstand422.22M Perf Week-3.45%
Market Cap147.41M Forward P/E- EPS next Y-0.15 Insider Trans141.01% Shs Float395.39M Perf Month-16.65%
Income-171.50M PEG- EPS next Q-0.07 Inst Own37.00% Short Float4.74% Perf Quarter-55.13%
Sales90.90M P/S1.62 EPS this Y6.90% Inst Trans-0.20% Short Ratio3.10 Perf Half Y-66.98%
Book/sh-0.14 P/B- EPS next Y62.50% ROA-81.60% Target Price4.33 Perf Year-75.52%
Cash/sh0.25 P/C1.41 EPS next 5Y17.60% ROE286.00% 52W Range0.31 - 2.75 Perf YTD-1.55%
Dividend- P/FCF- EPS past 5Y-6.30% ROI-136.80% 52W High-87.27% Beta1.73
Dividend %- Quick Ratio1.80 Sales past 5Y26.40% Gross Margin78.30% 52W Low11.11% ATR0.04
Employees400 Current Ratio1.90 Sales Q/Q31.60% Oper. Margin- RSI (14)37.83 Volatility7.78% 9.41%
OptionableYes Debt/Eq- EPS Q/Q6.10% Profit Margin- Rel Volume0.86 Prev Close0.35
ShortableYes LT Debt/Eq- EarningsNov 11 BMO Payout- Avg Volume6.05M Price0.35
Recom2.00 SMA20-7.90% SMA50-25.51% SMA200-59.26% Volume0 Change0.00%
Aug-07-20Downgrade Jefferies Hold → Underperform
May-19-20Downgrade JP Morgan Overweight → Neutral
Dec-02-19Initiated Guggenheim Buy
Oct-17-19Initiated H.C. Wainwright Buy $7
Apr-30-19Resumed Noble Capital Markets Outperform $13
Jun-15-18Initiated JP Morgan Overweight $11
Sep-08-17Initiated Morgan Stanley Equal-Weight $6
Jul-11-17Upgrade Oppenheimer Perform → Outperform
May-09-17Downgrade Oppenheimer Outperform → Perform
Nov-22-16Resumed Jefferies Buy $18
Nov-22-16Initiated Oppenheimer Outperform
Nov-07-16Resumed Guggenheim Buy
Apr-04-16Initiated Goldman Buy $10
Dec-08-15Reiterated Stifel Buy $10 → $14
Dec-08-15Reiterated Jefferies Buy $15 → $18
Sep-21-15Reiterated Jefferies Buy $7 → $15
Jun-09-15Initiated Guggenheim Buy
Jul-08-14Initiated FBR Capital Outperform $34
Apr-17-14Reiterated Noble Financial Buy $9 → $13
Jan-28-14Reiterated Noble Financial Buy $7.25 → $9
Jan-06-22 07:29AM  
Jan-04-22 06:20AM  
Dec-28-21 09:53AM  
Dec-13-21 06:08AM  
Dec-10-21 04:30PM  
Dec-08-21 06:50AM  
Nov-24-21 07:54AM  
Nov-22-21 10:40AM  
Nov-12-21 03:00AM  
Nov-11-21 06:50AM  
Nov-04-21 03:01PM  
Oct-27-21 05:00PM  
Oct-15-21 05:33PM  
Oct-05-21 01:28PM  
Oct-04-21 09:20AM  
Sep-02-21 06:50AM  
Aug-23-21 06:50AM  
Aug-19-21 08:01AM  
Aug-09-21 04:30PM  
Aug-04-21 08:05AM  
Jul-28-21 03:03PM  
Jul-26-21 06:50AM  
Jul-06-21 11:49AM  
Jun-29-21 08:58AM  
May-25-21 06:50AM  
May-24-21 07:00AM  
May-07-21 01:31AM  
May-06-21 10:56AM  
May-03-21 07:00AM  
Apr-29-21 10:34AM  
Apr-28-21 12:34PM  
Apr-09-21 11:16AM  
Apr-08-21 04:05PM  
Mar-15-21 10:32AM  
Mar-02-21 07:00PM  
Mar-01-21 10:05AM  
Feb-23-21 04:05PM  
Feb-18-21 10:16AM  
Feb-16-21 04:01PM  
Feb-11-21 09:02AM  
Feb-10-21 04:01PM  
Feb-03-21 12:50PM  
Jan-29-21 03:29AM  
Jan-12-21 08:34AM  
Dec-29-20 07:00AM  
Dec-17-20 03:47AM  
Dec-15-20 08:13AM  
Dec-11-20 10:34AM  
Nov-13-20 04:05PM  
Nov-11-20 12:29PM  
Nov-10-20 08:58AM  
Nov-09-20 04:01PM  
Nov-02-20 12:31PM  
Oct-29-20 07:00AM  
Oct-28-20 12:33PM  
Oct-26-20 04:05PM  
Oct-22-20 01:16PM  
Oct-09-20 08:00AM  
Oct-07-20 08:43AM  
Oct-06-20 10:03AM  
Oct-02-20 10:17AM  
Sep-25-20 09:02AM  
Sep-21-20 05:01PM  
Sep-16-20 01:54PM  
Sep-10-20 06:50AM  
Sep-09-20 04:05PM  
Aug-25-20 07:30AM  
Aug-14-20 10:34AM  
Aug-11-20 11:35AM  
Aug-06-20 09:45AM  
Jul-30-20 12:34PM  
Jul-29-20 06:50AM  
Jul-28-20 12:33PM  
Jul-15-20 06:50AM  
Jun-28-20 09:41AM  
Jun-25-20 04:49PM  
Jun-01-20 06:50AM  
May-27-20 09:47AM  
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donegan Michael CCAO and VP of FinanceNov 30Sale0.5429,79015,94799,368Dec 02 06:30 AM
Collins Cooper C.DirectorNov 18Buy0.581,000,000578,5002,236,864Nov 22 06:30 AM
Collins Cooper C.DirectorAug 18Buy0.72900,000648,0001,236,864Aug 19 06:01 AM
Collins Cooper C.DirectorAug 17Buy0.77100,00077,000336,864Aug 19 06:01 AM
Ling KarenDirectorAug 17Buy0.7533,44525,084130,309Aug 19 04:31 PM
BISARO PAULDirectorAug 16Buy0.7950,00039,500196,864Aug 18 06:03 AM
Thompson Tommy GDirectorAug 13Buy0.8711,0009,570715,600Aug 17 06:47 AM
DArecca JamesChief Financial OfficerAug 12Sale0.8793,33781,203123,830Aug 12 09:33 PM
Thompson Tommy GDirectorMay 14Buy1.065,0005,300704,600May 18 06:55 AM
Donegan Michael CCAO and VP FinanceMay 11Sale1.044,8425,03614,158May 12 08:44 PM
Walker Marlan DGeneral CounselMay 11Sale1.0421,59222,45628,908May 12 08:43 PM
BORKOWSKI EDWARDEVP, OperationsMay 11Sale1.0444,25246,02259,248May 12 08:39 PM
Milligan John C.K. IVSecretary/CEO of subsidiaryMay 11Sale1.0444,25246,0221,752,703May 12 08:38 PM
Finizio Robert GCEOMay 11Sale1.0467,69770,40517,991,637May 12 08:36 PM